Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | ATLAS trial: axitinib in RCC- despite reporting no significant difference, some optimism remains

David Quinn, MBBS, PhD, FRACP, from the USC Norris Comprehensive Cancer Center, Los Angeles, CA, presents the latest updates from the ATLAS study (NCT01599754), a clinical trial in which high-risk renal cell carcinoma patients received the VEGF tyrosine kinase inhibitor, axitinib or placebo. Interim analysis saw no significant difference in the two arms, however, later analysis found a significant benefit in the highest risk patients receiving axitinib. Following these positive results, further investigations will look into optimal dosing of axitinib in high-risk patients. This interview was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.